MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.82
+0.15
+1.96%
After Hours: 7.82 0 0.00% 16:00 09/27 EDT
OPEN
7.73
PREV CLOSE
7.67
HIGH
7.91
LOW
7.62
VOLUME
74.25K
TURNOVER
--
52 WEEK HIGH
9.90
52 WEEK LOW
5.82
MARKET CAP
383.68M
P/E (TTM)
-6.8012
1D
5D
1M
3M
1Y
5Y
Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following ...
PR Newswire - PRF · 09/01 12:34
Aeglea Biotherapeutics Inc (AGLE) CFO Jonathan Alspaugh Bought $262,822 of Shares
GuruFocus News · 08/19 16:15
Insider Trends: 90-Day Insider Selling Trend at Aeglea BioTherapeutics Slowed with Acquisition of Shares
MT Newswires · 08/18 17:40
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Analysts Are Betting On Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) With A Big Upgrade This Week
Shareholders in Aeglea BioTherapeutics, Inc. ( NASDAQ:AGLE ) may be thrilled to learn that the analysts have just...
Simply Wall St. · 08/10 05:00
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
As you might know, Aeglea BioTherapeutics, Inc. ( NASDAQ:AGLE ) just kicked off its latest second-quarter results with...
Simply Wall St. · 08/08 07:06
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/05 14:05
BRIEF-Aeglea Biotherapeutics Reports Second Quarter 2021 Financial Results And Corporate Highlights
reuters.com · 08/05 13:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGLE. Analyze the recent business situations of Aeglea Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGLE stock price target is 14.50 with a high estimate of 22.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 42.59M
% Owned: 86.80%
Shares Outstanding: 49.06M
TypeInstitutionsShares
Increased
28
2.19M
New
3
65.14K
Decreased
26
2.43M
Sold Out
9
323.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Non-Executive Chairman/Independent Director
Russell Cox
President/Chief Executive Officer/Director
Anthony Quinn
Chief Financial Officer
Jonathan Alspaugh
Chief Operating Officer
Leslie Sloan
Vice President/Controller
Steven Weber
General Counsel
Jim Kastenmayer
Other
Michael Hanley
Director
Marcio Souza
Independent Director
Sara Brownstein
Independent Director
V. Bryan Lawlis
Independent Director
Alison Lawton
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
Sandesh Mahatme
Independent Director
Armen Shanafelt
No Data
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.